Latest Daily News

More Stories
June 4, 2018

The findings of a pan-cancer study have indicated that all patients with microsatellite instability-high (MSI-H) tumors should be tested for Lynch syndrome, regardless of cancer type or their personal or family history of cancer.

Read more
June 3, 2018

Monday InBriefs: Highlights from ASCO18

Read more

June 3, 2018

John Mendelsohn, MD, is internationally renowned for his contributions to basic science and clinical trials that helped explicate the role of EGFRs on cancer cell proliferation.

Read more

June 3, 2018

Analyzing cell-free DNA (cfDNA) circulating in plasma or serum can help oncologists determine the genotype of tumors noninvasively to guide treatment decisions and may eventually allow them to monitor treatment response, predict recurrence, and screen for cancer.

Read more

June 2, 2018

Rearranged during transfection (RET) is an oncogene activated by RET fusions or RET mutations. RET fusions are associated with 2% of non–small cell lung cancers (NSCLCs), 10%-20% of papillary and other thyroid cancers, and smaller proportions of other cancers.

Read more

June 1, 2018

In November, the U.S. Food and Drug Administration announced its approval of the first breakthrough-designated, next-generation sequencing (NGS)-based diagnostic test, the FoundationOne CDx.

Read more

May 15, 2018

Douglas R. Lowy, MD, will receive the 2018 Science of Oncology Award. The award recognizes outstanding contributions to basic or translational research in cancer.

Read more

June 7, 2016

The Clinical Science Symposium, “Precision Medicine: Making Progress for Patient Benefit,” detailed 3 large-scale efforts leveraging innovative trial designs and cutting-edge technology to break critical ground in the ability to pinpoint and use viable targeted therapies for individual patients.

Read more

June 7, 2016

Because immune responses are evolving and dynamic over time, expression of a single biomarker to select patients for treatment will really not be feasible and we should not continue on the single biomarker path.

Read more
June 6, 2016

The session “The Immune System and Cancer,” discussed the nuts and bolts of and current thinking about immunology and cancer and the implications for future research and therapy. 

Read more

May 26, 2016

Several Education Sessions focus on the increasing importance of immunotherapies in oncology practice and on future research directions in the field. From currently approved checkpoint inhibitors to on-the-horizon ideas, these sessions offer glimpses into a promising area of cancer therapy.

Read more

May 26, 2016

The field of immuno-oncology has revolutionized cancer care over the past decade and continues to yield new, exciting results. ASCO, in collaboration with the Society for Immunotherapy of Cancer (SITC), will be holding its first symposium on immuno-oncology next year in Orlando, Florida.

Read more
May 21, 2015

In this article from 2013, Drs. Yujie Zhao and Alex A. Adjei discuss inhibiting MEK for cancer therapy.

Read more

May 21, 2015

In this article from 2012, Dr. Grant McArthur discusses how the RAS/RAF/MEK/ERK pathway functions in cancer.

Read more
May 29, 2015

Multiple studies indicate that mutant IDH is a valid target for cancer drug development in possibly addressing a broad range of solid and hematologic tumors.

Read more
May 30, 2015

Comparative effectiveness research is a new priority in cancer research and is increasing efficiency in research and changing everyday practice and policy.

Read more
May 30, 2015

Wendy Kohlmann, Marjan Champine, and Dr. Sarah Colonna present their thoughts on discussing genetic testing with patients and their families, including obtaining informed consent, explanation of mutations, and recommendations for genetic counseling.

Read more
May 31, 2015

Results from the phase III IFCT-GFPC-0701 MAPS trial found that the addition of bevacizumab to standard chemotherapy in patients with malignant pleural mesothelioma prolonged overall survival by 2.75 months.

Read more
May 31, 2015

Advances made in next generation sequencing have allowed germline mutations to be increasingly identified in tumors and normal DNA. The significance of these findings, including whether results arising from germline testing should be returned to patients, was discussed during this session.

Read more
June 7, 2015

An Education Session at the ASCO Annual Meeting reviewed data on neoadjuvant and adjuvant therapy, targeted therapies for metastatic disease, and management of brain metastases.

Read more